Spanish consensus on the diagnosis and management of adrenocortical carcinoma
Endocrine-Related Cancer · 01.05.2025 · 32 (5)
DOI: 10.1530/erc-25-0034 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Endocrine-Related Cancer, online erschienen am 11.04.2025. Verfasst von Marta Araujo-Castro und 15 weiteren Autor:innen. Hauptthemen laut MEDLINE: Adrenocortical Carcinoma, Adrenal Cortex Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 188 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Adrenocortical carcinoma (ACC) is a rare endocrine malignancy with an estimated incidence of 0.7–2 cases per million/year. The rarity of this disease, coupled with limited preclinical models and clinical trials, has hindered progress, resulting in poor outcomes, with a 5-year survival rate of approximately 35%. Currently, the only available curative treatment is complete surgical resection of the adrenal tumor. For unresectable or metastatic ACC, the current standard therapeutic modalities are mitotane, chemotherapy, radiotherapy and locoregional treatments; however, these are noncurative. Mitotane has an adrenolytic and anti-steroidogenic effect, and it is used in the adjuvant setting for high-risk patients, as systemic therapy for metastatic disease, and/or to control hormonal secretion. While key pathways in ACC pathogenesis have been identified as potential therapeutic targets, results with targeted therapies remain modest, showing that there is a clinical unmet need for novel treatments or new combinations of exiting drugs. Effective management requires a multidisciplinary team of experts to optimize outcomes for patients. This article presents a multidisciplinary consensus on the diagnosis, management, prognosis and follow-up of patients with ACC, and the approach to two special contexts, ACC in pregnant women and hormone-producing ACC. The consensus was coordinated by the Spanish Society of Endocrinology and Nutrition (SEEN) and the Spanish Group of Neuroendocrine and Endocrine Tumors (GETNE), with contribution from experts from related societies including the Spanish Association of Surgeons (AEC), Spanish Society of Urology (AEU), Anatomic-Pathology (SEAP), Nuclear Medicine (SEMNIM), Medical Oncology (SEOM) and Radiotherapeutic Oncology (SEOR).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
ORCID-Profile: Marta Araujo-Castro, Cristina Álvarez-Escola, Jaume Capdevila
Zitieren
APA
Araujo-Castro, M., Álvarez-Escola, C., Casteràs, A., Carmona-Bayonas, A., Chiara, M. D., Hanzu, F. A., Hernando, J., Vercher-Conejero, J. L., Rodríguez-Fraile, M., Gómez Dos Santos, V., Jimenez-Fonseca, P., Giraldo, A., Valdés, N., Vidal, O., Del Olmo-García, M., & Capdevila, J. (2025). Spanish consensus on the diagnosis and management of adrenocortical carcinoma. Endocrine-Related Cancer, 32(5). https://doi.org/10.1530/erc-25-0034
Vancouver
Araujo-Castro M, Álvarez-Escola C, Casteràs A, Carmona-Bayonas A, Chiara MD, Hanzu FA, et al. Spanish consensus on the diagnosis and management of adrenocortical carcinoma. Endocrine-Related Cancer. 2025;32(5). doi:10.1530/erc-25-0034
BibTeX
@article{AraujoCastro2025,
author = {Araujo-Castro, Marta and Álvarez-Escola, Cristina and Casteràs, Ana and Carmona-Bayonas, Alberto and Chiara, María-Dolores and Hanzu, Felicia A and Hernando, Jorge and Vercher-Conejero, José L and Rodríguez-Fraile, Macarena and Gómez Dos Santos, Victoria and Jimenez-Fonseca, Paula and Giraldo, Alexandra and Valdés, Nuria and Vidal, Oscar and Del Olmo-García, Maribel and Capdevila, Jaume},
title = {Spanish consensus on the diagnosis and management of adrenocortical carcinoma},
journal = {Endocrine-Related Cancer},
year = {2025},
volume = {32},
number = {5},
doi = {10.1530/erc-25-0034}
}
EUVIMED